Abstract
This editorial discusses past studies which have looked at whether oral contraceptives containing drospirenone had an increased risk of venous thromboembolism (VTE) compared to earlier generation oral contraceptives. It discusses the conclusions of those studies and possible arguments for both sides of the fence.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
